Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Abstract:
NANOBIOTIX (Euronext: NANO-ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced the appointment of Thierry Otin as Head of Manufacturing and Supply. The appointment strengthens the Nanobiotix organisation, Mr Otin will be responsible for the manufacturing plans to move the lead product, NBTXR3, from clinical trials into full commercialization as from 2016.

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply

Paris, France | Posted on April 15th, 2014

Prior to joining Nanobiotix, Mr Otin was the Quality Site Manager (EU Sterile) at Roche and before then, he worked at LFB Biotechnologies as the Head Pharmacist (Pharmaceutical Qualified Person) and Quality Director. Prior to this, he worked in QA/GMP and manufacturing with world class companies including, Schering CISBiointernational, Institut de Formation des Industries de Santé (IFIS), UCB, Delagrange and Rhône-Poulenc (Roger Bellon and Specia). He has a degree in biology and has a doctorate in Pharmacy from the University of Strasbourg.

Laurent Levy, CEO of Nanobiotix said: "Thierry Otin joins us having had over 30 years' experience in the global pharmaceutical industry which includes 12+ years' experience of injectable drug production management and 11+ years in QA senior compliance management. This wealth of expertise will be invaluable to us as we move our lead product to commercialization. We welcome him to the team."

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.
Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

For more information, please click here

Contacts:
Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


Media Relations
France - NewCap
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59
/

Financial communication and investors relations
NewCap.
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53


Instinctif Partners
Melanie Toyne Sewell / Katherine Lynch / Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Maximum Precision in 3D Printing: New complete solution makes additive manufacturing standard for microfabrication February 26th, 2015

Real-time observation of bond formation by using femtosecond X-ray liquidography February 26th, 2015

Bruker-Sponsored Sixth AFM BioMed Conference Highlights Increasing Impact of AFM in Biological Applications February 26th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Nanomedicine

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations: UCLA bioengineers develop platform that offers personalized approach to treatment February 24th, 2015

Optical nanoantennas set the stage for a NEMS lab-on-a-chip revolution February 24th, 2015

Together, nanotechnology and genetic interference may tackle 'untreatable' brain tumors: Tel Aviv University researchers' groundbreaking strategy stops brain tumor cell proliferation with targeted nanoparticles February 24th, 2015

Announcements

Maximum Precision in 3D Printing: New complete solution makes additive manufacturing standard for microfabrication February 26th, 2015

Real-time observation of bond formation by using femtosecond X-ray liquidography February 26th, 2015

Bruker-Sponsored Sixth AFM BioMed Conference Highlights Increasing Impact of AFM in Biological Applications February 26th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Appointments/Promotions/New hires/Resignations/Deaths

KIT Increases Commitment in Asia: DAAD Funds Two New Projects: Strategic Partnerships with Chinese Universities and Communi-cation Technologies Network February 22nd, 2015

SouthWest Nanotechnologies CEO Dave Arthur Appointed to the Board of Affiliates of Rice University Professional Science Master’s Program February 13th, 2015

Nexeon Board Changes Announced January 29th, 2015

Rice's Naomi Halas to direct Smalley Institute: Optics pioneer will lead Rice's multidisciplinary science institute January 15th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE